The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94 99. 38. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875 1884. 39. Zhao YY, Weir MA, Manno M et al. New fibrate use and acute renal outcomes in elderly adults a population-based study. Ann Intern Med 2012; 156: 560 569. 40. Cerkauskiene R, Kaminskas A, Kaltenis P et al. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephritic syndrome]. Medicina 2003; 39(Suppl 1): 82 87. 41. Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U et al. Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephritic syndrome. J Med Assoc Thai 1999; 82(Suppl 1): S122 S128. 42. Goren A, Stankiewicz H, Goldstein R et al. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. Pediatrics 1991; 88: 265 268. 43. Hogg RJ, Lee J, Nardelli N et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 467 474. SUMMARY OF RECOMMENDATION STATEMENTS Chapter 1: ASSESSMENT OF LIPID STATUS IN ADULTS WITH CKD 1.1: In adults with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (1C) 1.2: In adults with CKD (including those treated with chronic dialysis or kidney transplantation), follow-up measurement of lipid levels is not required for the majority of patients. 